Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | WRN | Q14191 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27605628 | 0.85 | ALDH1A1 (0.39) | FDPSTHRBNOS1ALDH1A1LMNA | |
| SCHEMBL11051288 | 0.81 | DGKA (0.41) | NOS1ALDH1A1TSHRLMNA | |
| SCHEMBL278457 | 0.78 | — | — | |
| SCHEMBL10751495 | 0.77 | NOS1 (0.32) | FDPSNOS1ALDH1A1MEN1TSHR | |
| SCHEMBL16861454 | 0.76 | NOS1 (0.37) | NOS1MEN1TSHRKMT2A | |
| SCHEMBL128494 | 0.75 | — | — | |
| SCHEMBL2853189 | 0.74 | — | — | |
| SCHEMBL440250 | 0.74 | — | — | |
| SCHEMBL28346497 | 0.73 | KDM4E (0.31) | ALDH1A1ELANESMN1; SMN2 | |
| SCHEMBL11242896 | 0.73 | KMT2A (0.36) | HPGDTSHRKMT2AELANELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0293220-B1 | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | ORTHO PHARMA CORP (US) | 1994-08-31 | — | — | EP | claimed |
| EP-0293220-A2 | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-11-30 | — | — | EP | claimed |
| CN-114929697-A | Azabenzimidazole compounds and medicaments | 日本新药株式会社 | 2022-08-19 | — | — | CN | disclosed |
| CN-113329791-A | 9-substituted amino-triazoloquinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and uses thereof | 默沙东公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-3853209-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020058945-A1 | METHODS OF PRODUCING PYRAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2020-03-26 | — | — | WO | disclosed |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2603218-B1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-09-11 | — | — | US | disclosed |
| EP-2603218-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
| EP-0293220-B1 | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | ORTHO PHARMA CORP (US) | 1994-08-31 | — | — | EP | disclosed |
| EP-0248594-B1 | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same | ORTHO PHARMA CORP (US) | 1993-11-24 | — | — | EP | disclosed |
| US-5242940-A | Antiinflammatory agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1993-09-07 | — | — | US | disclosed |
| US-5164381-A | Cardiovascular, antiinflammatory | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| US-5051518-A | Antiinflammatory agents and cardiovascular disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-09-24 | — | — | US | disclosed |
| US-4826868-A | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| EP-0293220-A2 | Pharmacologically active 2-and 3-substituted (1', 5'-diaryl-3-pyrazolyl)-N-Hydroxypropanamides and method for synthesizing | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-11-30 | — | — | EP | disclosed |
| EP-0248594-A2 | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-12-09 | — | — | EP | disclosed |
| US-4673429-A | Nitrification-inhibiting 1-hydroxypyrazole derivatives | BASF AKTIENGESELLSCHAFT (DE) | 1987-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041024-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | FDPS 2928/4885THRB 1193/4885NOS1 953/4885 |
| US-20160060249-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | FDPS 2928/4885THRB 1193/4885NOS1 953/4885 |
| US-20140256949-A1 | QUINOLYL AMINES AS KINASE INHIBITORS | ABL1, MAP3K20, MAP3K19 | FDPS 2928/4885THRB 1193/4885NOS1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.